NABI-HB (Biotest Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the NABI-HB drug offered from Biotest Pharmaceuticals Corporation. This Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Biotest Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN |
| SUBSTANCE NAME: | HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] |
| ROUTE: | INTRAMUSCULAR |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2010-03-10 |
| END MARKETING DATE: | 0000-00-00 |
NABI-HB HUMAN PRESCRIPTION DRUG Details:
| Item Description | NABI-HB from Biotest Pharmaceuticals Corporation |
| LABELER NAME: | Biotest Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 312([iU]/mL) |
| START MARKETING DATE: | 2010-03-10 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 59730-4202_b2145184-7093-495f-a36b-8bf1d56b6a09 |
| PRODUCT NDC: | 59730-4202 |
| APPLICATION NUMBER: | BLA991442 |
Other HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:
